EMD for Treatment of Proximal Class-II Furcation Involvements

Enamel Matriz Derivate for Treatment of Proximal Class II Furcation Defects: a Randomized Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03320135

Acronym

OFD

Enrollment

Registered

2017-10-25

Start date

2017-10-20

Completion date

2019-05-20

Last updated

2019-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Aggressive Periodontitis

Keywords

enamel matrix derivative, proximal furcation, randomized clinical trial

Brief summary

The aim of the present study is to evaluate the clinical response of proximal furcations treated with enamel matrix derivative proteins (EMD).

Detailed description

Proximal class-II furcation represents a challeng to periodontal therapy. Studies show that the ultrasonic non-surgical therapy doesn't work in these defects and the guided tissue regeneration therapy with membranes also demonstrates an unpredictable improvement. Therefore, enamel matrix derivative proteins (EMD) have been proposed as a periodontal regenerative procedure due to their fundamental role in cementum development.

Interventions

PROCEDUREEnamel matrix derivative proteins

Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.

PROCEDUREOpen Flap debridement

Open flap debridement will be performed to decontaminate the proximal furcation involvements.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 35 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosis of generalized aggressive periodontitis (Armitage, 1999; American Academy of Periodontology, 2015); * Have undergone a first approach for periodontal treatment (full-mouth ultrasonic debridement); * Presence of one proximal class-II furcation presenting probing depth \> 4 mm and bleeding on probing ; * Good general health; * Agree to participate in the study and sign the informed consent form (TCLE) after explaining the risks and benefits;

Exclusion criteria

* Systemic problems (cardiovascular alterations, blood dyscrasias, immunodeficiency - ASA III / IV / V) that contraindicate the periodontal procedure; * Have used antibiotics and anti-inflammatories in the last six months; * Smoke ≥ 10 cigarettes/day; * Pregnant or lactating; * Chronic use of medications that may alter the response of periodontal tissues; * Indication of antibiotic prophylaxis for dental procedures;

Design outcomes

Primary

Measure	Time frame	Description
Horizontal clinical attachment level	1 year	horizontal component of the defect

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026